News
-
-
PRESS RELEASE
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
enVVeno Medical Corporation to present new interim venous ulcer healing data from VenoValve U.S. trial at VAM2024. Study focuses on treatment of venous disease with innovative bioprosthetic solutions -
-
PRESS RELEASE
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
enVVeno Medical Corporation reported ending the quarter with $42.9 million cash and investments to fund operations through 2025, presenting positive data at the 46th Annual Charing Cross Symposium -
-
PRESS RELEASE
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
enVVeno Medical presents positive efficacy data on VenoValve from SAVVE U.S. pivotal trial at Charing Cross International Symposium, showing clinical improvement for severe CVI patients -
-
PRESS RELEASE
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
enVVeno Medical Corporation to present additional topline efficacy data from VenoValve U.S. pivotal trial at 2024 Charing Cross International Symposium in London. Data to review clinical status of severe Chronic Venous Insufficiency patients post VenoValve implantation -
-